SLC22A3 and acute myeloid leukemia: Moreover, Kaplan–Meier analysis based on Beat AML patients also revealed this clinical significance between SLC22A3 high-expression and longer OS in both whole-cohort AML and CN-AML (P = 0.033 and 0.032; Fig. 1G).